Physician profile
Michael A Warner
NPI 1265458293
$3,250.07
in general payments reported to CMS, 2019-2025
15 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $273 · 2021: $638 · 2022: $1,256 · 2023: $390 · 2024: $130 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,902.47 | 2019-2023 | Tepezza |
| Merz Pharmaceuticals, LLC | $307.86 | 2021-2025 | Xeomin |
| Ivantis, INC | $261.18 | 2021 | |
| Amgen INC. | $201.12 | 2025 | Tepezza |
| Merz North America, INC. | $182.47 | 2019 | |
| Abbvie INC. | $89.04 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $88.17 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $39.34 | 2024 | Xdemvy |
| Alcon Vision LLC | $38.33 | 2022 | |
| Aerie Pharmaceuticals, INC. | $33.24 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $28.73 | 2019 | |
| Janssen Biotech, INC. | $20.83 | 2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $20.79 | 2020 | |
| Abiomed | $20.11 | 2024 | Impella |
| Galderma Laboratories, L.P. | $16.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.